Efficacy of intravenous nalbuphine for managing post-anaesthesia shivering : a systematic review and meta-analysis of randomised controlled trials with trial sequential analysis
Nair, Abhijit Dudhedia, Ujjwalraj Rangaiah, Manamohan Panchawagh, Suhrud
Nair, Abhijit
Dudhedia, Ujjwalraj
Rangaiah, Manamohan
Panchawagh, Suhrud
Citations
Altmetric:
Affiliation
IBRA Hospital; Dr. L. H. Hiranandani Hospital; Walsall Healthcare NHS Trust; Smt. Kashibai Navale Medical College and General Hospital
Other Contributors
Publication date
2023-10-16
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background and aims: Post-anaesthesia shivering is distressing and is observed after spinal and general anaesthesia. Nalbuphine, a partial mu-opioid receptor antagonist with kappa-opioid receptor agonist properties, has been successfully used to manage post-anaesthesia shivering.
Methods: After registering the review with the International Prospective Register of Systematic Reviews (PROSPERO), we searched PubMed/Medline, Scopus, Ovid, Cochrane Library and clinicaltrials.gov with keywords for randomised controlled trials. The risk of bias-2 (RoB-2) scale was used to assess the quality of evidence. We also used Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines to evaluate the strength of evidence and trial sequential analysis to validate the conclusions.
Results: Of the 240 articles, 10 were considered eligible for review (700 patients, 350- nalbuphine, 350- control or placebo). When compared to placebo, the success rate of nalbuphine controlling shivering was significantly better (risk ratio [RR]: 2.37, 95% confidence interval [CI]:1.91, 2.94; P = 0.04, I² = 94%), but comparable to the control group drugs (opioids, dexmedetomidine, ondansetron, pethidine). Compared to placebo, shivering recurrence was significantly less with nalbuphine than with placebo (RR: 0.47, 95% CI: 0.26, 0.83; P = 0.01, I² = 61%), but comparable with the control group. The incidence of postoperative nausea/vomiting (PONV) was significantly less with nalbuphine when compared to the control group (RR: 0.67, 95% CI: 0.47, 0.95; P = 0.02, I² = 37%), but PONV in the nalbuphine group was comparable to placebo (RR: 1.20, 95% CI: 0.68, 2.12; P = 0.54, I² = 0%). Other outcomes, like the grade of shivering and hypotension, were comparable between the nalbuphine and control groups.
Conclusion: Nalbuphine successfully controls post-anaesthesia shivering and reduces the recurrence of shivering.
Citation
Nair A, Dudhedia U, Rangaiah M, Panchawagh S. Efficacy of intravenous nalbuphine for managing post-anaesthesia shivering: A systematic review and meta-analysis of randomised controlled trials with trial sequential analysis. Indian J Anaesth. 2023 Oct;67(10):853-865.
Type
Article